nach oben

Tumor Biology

Erschienen in:

30.12.2015 | Review

Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut

verfasst von: Arif Bashir, Abid Yousuf Miskeen, Younis Mohammad Hazari, Syed Asrafuzzaman, Khalid Majid Fazili

Erschienen in: Tumor Biology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Fusobacterium nucleatum is an identified proinflammatory autochthonous bacterium implicated in human colorectal cancer. It is also abundantly found in patients suffering from chronic gut inflammation (inflammatory bowel disease), consequently contributing to the pathogenesis of colorectal cancer. Majority of the studies have reported that colorectal tumors/colorectal adenocarcinomas are highly enriched with F. nucleatum compared to noninvolved adjacent colonic tissue. During the course of multistep development of colorectal cancer, tumors have evolved many mechanisms to resist the antitumor immune response. One of such favorite ploy is providing access to pathogenic bacteria, especially F. nucleatum in the colorectal tumor microenvironment, wherein both (colorectal tumors and F. nucleatum) exert profound effect on each other, consequently attracting tumor-permissive myeloid-derived suppressor cells, suppressing cytotoxic CD8+ T cells and inhibiting NK cell-mediated cancer cell killing. In this review, we have primarily focused on how this bug modulates the immune response, consequently rendering the antitumor immune cells inactive.

Kostic AD et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207–15.CrossRefPubMedPubMedCentral

Rubinstein MR et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195–206.CrossRefPubMedPubMedCentral

Tahara T et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014;74(5):1311–8.CrossRefPubMedPubMedCentral

Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014;15(3):317–28.CrossRefPubMedPubMedCentral

Bashir A et al. Fusobacterium nucleatum: an emerging bug in colorectal tumorigenesis. Eur J Cancer Prev. 2015;24(5):373–85.CrossRefPubMed

Tjalsma H et al. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10(8):575–82.CrossRefPubMed

Ford AC, Moayyedi P, Hanauer SB. Ulcerative colitis. BMJ. 2013;346:f432.CrossRefPubMed

Yang T et al. Microbiota impact on the epigenetic regulation of colorectal cancer. Trends Mol Med. 2013;19(12):714–25.CrossRefPubMed

Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639–45.CrossRefPubMed

10.

Couturier-Maillard A et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest. 2013;123(2):700–11.PubMedPubMedCentral

11.

Jostins L et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–24.CrossRefPubMedPubMedCentral

12.

Gevers D et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15(3):382–92.CrossRefPubMedPubMedCentral

13.

Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146(6):1489–99. doi:10.1053/j.gastro.2014.02.009.CrossRefPubMedPubMedCentral

14.

Minot S et al. The human gut virome: inter-individual variation and dynamic response to diet. Genome Res. 2011;21(10):1616–25. doi:10.1101/gr.122705.111.CrossRefPubMedPubMedCentral

15.

Norman JM, Handley SA, Virgin HW. Kingdom-agnostic metagenomics and the importance of complete characterization of enteric microbial communities. Gastroenterology. 2014;146(6):1459–69. doi:10.1053/j.gastro.2014.02.001.CrossRefPubMedPubMedCentral

16.

Virgin HW. The virome in mammalian physiology and disease. Cell. 2014;157(1):142–50.CrossRefPubMedPubMedCentral

17.

Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121–41.CrossRefPubMedPubMedCentral

18.

Cario E. Microbiota and innate immunity in intestinal inflammation and neoplasia. Curr Opin Gastroenterol. 2013;29(1):85–91.CrossRefPubMed

19.

Sansone P, Bromberg J. Environment, inflammation, and cancer. Curr Opin Genet Dev. 2011;21(1):80–5.CrossRefPubMed

20.

Liu H, Redline RW, Han YW. Fusobacterium nucleatum induces fetal death in mice via stimulation of TLR4-mediated placental inflammatory response. J Immunol. 2007;179(4):2501–8.CrossRefPubMed

21.

Swidsinski A et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut. 2011;60(1):34–40.CrossRefPubMed

22.

Irrazabal T et al. The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell. 2014;54(2):309–20.CrossRefPubMed

23.

McCoy AN et al. Fusobacterium is associated with colorectal adenomas. PLoS One. 2013;8(1):e53653.CrossRefPubMedPubMedCentral

24.

Dharmani P et al. Fusobacterium nucleatum infection of colonic cells stimulates MUC2 mucin and tumor necrosis factor alpha. Infect Immun. 2011;79(7):2597–607.CrossRefPubMedPubMedCentral

25.

Castellarin M et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22(2):299–306.CrossRefPubMedPubMedCentral

26.

Kostic AD et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22(2):292–8.CrossRefPubMedPubMedCentral

27.

Marchesi JR et al. Towards the human colorectal cancer microbiome. PLoS One. 2011;6(5):e20447. doi:10.1371/journal.pone.0020447.CrossRefPubMedPubMedCentral

28.

Strauss J et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011;17(9):1971–8.CrossRefPubMed

29.

Kostic AD et al. Microbes and inflammation in colorectal cancer. Cancer Immunol Res. 2013;1(3):150–7.CrossRefPubMed

30.

Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.CrossRefPubMedPubMedCentral

31.

Mima K et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015;1(5):653–61.CrossRefPubMedPubMedCentral

32.

Moretta L et al. Human natural killer cells: origin, clonality, specificity, and receptors. Adv Immunol. 1994;55:341–80.CrossRefPubMed

33.

Levin AM et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature. 2012;484(7395):529–33.CrossRefPubMedPubMedCentral

34.

Koch J et al. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 2013;34(4):182–91. doi:10.1016/j.it.2013.01.003.CrossRefPubMed

35.

Seidel E, Glasner A, Mandelboim O. Virus-mediated inhibition of natural cytotoxicity receptor recognition. Cell Mol Life Sci. 2012;69(23):3911–20. doi:10.1007/s00018-012-1001-x.CrossRefPubMed

36.

Gur C et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–55. doi:10.1016/j.immuni.2015.01.010.CrossRefPubMedPubMedCentral

37.

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.CrossRefPubMed

38.

Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49–60.CrossRefPubMed

39.

Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38–48.CrossRefPubMedPubMedCentral

40.

van den Boorn JG, Hartmann G. Turning tumors into vaccines: co-opting the innate immune system. Immunity. 2013;39(1):27–37.CrossRefPubMed

41.

Crespo J et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013;25(2):214–21. doi:10.1016/j.coi.2012.12.003.CrossRefPubMedPubMedCentral

42.

Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014;35(2):51–60. doi:10.1016/j.it.2013.10.001.CrossRefPubMed

43.

Johnston RJ et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26(6):923–37. doi:10.1016/j.ccell.2014.10.018.CrossRefPubMed

Titel: Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut
verfasst von: Arif Bashir
Abid Yousuf Miskeen
Younis Mohammad Hazari
Syed Asrafuzzaman
Khalid Majid Fazili
Publikationsdatum: 30.12.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 3/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4724-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

St Gallen molecular subtypes in feline mammary carcinoma and paired metastases—disease progression and clinical implications from a 3-year follow-up study

A five-variable signature predicts radioresistance and prognosis in nasopharyngeal carcinoma patients receiving radical radiotherapy

Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis

Authentication of newly established human esophageal squamous cell carcinoma cell line (YM-1) using short tandem repeat (STR) profiling method

The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy

The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie